Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Operating Leases (2019 - 2025)

Niagen Bioscience (NAGE) has disclosed Operating Leases for 7 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 68.98% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, up 68.98% year-over-year, with the annual reading at $2.8 million for FY2025, 68.98% up from the prior year.
  • Operating Leases for Q4 2025 was $2.8 million at Niagen Bioscience, down from $3.1 million in the prior quarter.
  • The five-year high for Operating Leases was $4.5 million in Q2 2022, with the low at $1.4 million in Q1 2021.
  • Average Operating Leases over 5 years is $3.3 million, with a median of $3.4 million recorded in 2021.
  • The sharpest move saw Operating Leases surged 567.43% in 2021, then tumbled 50.71% in 2024.
  • Over 5 years, Operating Leases stood at $4.2 million in 2021, then decreased by 14.81% to $3.5 million in 2022, then dropped by 6.75% to $3.3 million in 2023, then tumbled by 49.79% to $1.7 million in 2024, then surged by 68.98% to $2.8 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $2.8 million, $3.1 million, and $3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.